In Vitro Cytotoxicity and Cytokine Production by Lipid-Substituted Low Molecular Weight Branched PEIs Used for Gene Delivery
Source abstract
Abstract
Lipid-modified low molecular weight branched polyethyleneimines (PEIs) are promising non-viral gene delivery systems that have been successfully explored for treatment of various diseases. The present study aims to determine in vitro safety of these delivery systems based on assessment of cytotoxicity with peripheral blood mononuclear cells (PBMCs), hemolysis with human red blood cells (RBC) and cytokine secretion from several sources of PBMCs. The viability of cells treated with lipopolymer/pDNA complexes was dependent on the polymer:pDNA ratio used but remained low at therapeutically relevant concentrations for most lipopolymers, except for the propionic acid substituted PEIs. The extent of hemolysis was minimal and below the accepted safety levels with most of the lipopolymers; however, some linoleic acid substituted PEIs yielded significant hemolysis activity. Unlike strong cytokine secretion from PMA/IO stimulated cells, most lipopolymer/pDNA complexes remained non-responsive, showing minimal changes in cytokine secretion (TNF-α, IL-6 and IFN-γ) irrespective of the lipopolymer/pDNA formulations. The 0.6 kDa PEI with lauric acid substituent displayed slight cytokine upregulation, however it remained low relative to the positive controls. This study demonstrated that the lipid modified LMW PEIs are expected to be safe in contact with blood components. However, close attention to lipopolymer concentration and ratio of polymer to pDNA in formulations might be required for individual lipopolymers for optimal safety response in nucleic acid therapies. STATEMENT OF SIGNIFICANCE: This manuscript investigated the safety aspects of various lipid modified low molecular weight polyethylenimine (LMW-PEI) polymers employed for pDNA delivery through in vitro studies. Using peripheral blood mononuclear cells (PBMCs) from multiple sources, we show that the hemolysis ability was minimal for most polymers, although a particular lipid substituent (linoleic acid) at specific ratios exhibited hemolysis. The levels of pro-inflammatory cytokines (TNF-α, IL-6 and IFN-γ) were slightly upregulated only with a lauric acid substituted 0.6PEI, but remained low relative to positive control treatments. We further report the beneficial effect of polyacrylic acid additives on hemolysis and cytokine secretion to a reasonable extent. This study confirms the feasibility of using LMW-PEI as safe delivery agents for various therapeutic purposes.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Virus-based gene therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (89)
Show source-provided references
1. In vivo gene delivery mediated by non-viral vectors for cancer therapy10.1016/j.jconrel.2020.06.038 ↗
2. Design and gene delivery activity of modified polyethylenimines10.1016/S0169-409X(01)00202-2 ↗
3. D.W. Pack, A.S. Hoffman, S. Pun, P.S. Stayton, DESIGN AND DEVELOPMENT OF POLYMERS FOR GENE DELIVERY, 4 (2005) 581–593. https://doi.org/10.1038/nrd1775.10.1038/nrd1775 ↗
4. Formation and intracellular trafficking of lipoplexes and polyplexes10.1016/j.ymthe.2004.12.006 ↗
5. Progress and problems with the use of viral vectors for gene therapy10.1038/nrg1066 ↗
6. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine10.1073/pnas.92.16.7297 ↗
7. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex10.1016/j.vaccine.2004.09.009 ↗
8. A linear polyethylenimine mediated siRNA-based therapy targeting human epidermal growth factor receptor in SPC-A1 xenograft mice10.1186/2213-0802-1-2 ↗
9. Evaluation of proinflammatory cytokine production induced by linear and branched polyethylenimine/plasmid DNA complexes in mice10.1124/jpet.105.100669 ↗
10. Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle10.1002/(SICI)1097-4636(19990605)45:3<268::AID-JBM15>3.0.CO;2-Q ↗
11. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine10.1016/S0168-3659(03)00076-2 ↗
12. Impact of Lipid Substitution on Assembly and Delivery of siRNA by Cationic Polymers10.1002/mabi.201000402 ↗
13. Breathing New Life into TRAIL for Breast Cancer Therapy: co-Delivery of pTRAIL and Complementary siRNAs Using Lipopolymers, Hum10.1089/hum.2019.096 ↗
14. Cholesterol grafted cationic lipopolymers: potential siRNA carriers for selective chronic myeloid leukemia therapy10.1002/jbm.a.36837 ↗
15. Small hydrophobe substitution on polyethylenimine for plasmid DNA delivery: optimal substitution is critical for effective delivery10.1016/j.actbio.2016.01.025 ↗
16. Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells10.1093/nar/29.18.3882 ↗
17. Effect of basic fibroblast growth factor in mouse embryonic stem cell culture and osteogenic differentiation10.1002/term.532 ↗
18. Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells10.1002/jbm.a.35846 ↗
19. siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo10.1016/j.ejpb.2018.06.018 ↗
20. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia10.1016/j.jconrel.2015.12.052 ↗
21. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells10.1016/j.actbio.2017.11.036 ↗
22. Novel targets for sensitizing breast cancer cells to TRAIL-induced apoptosis with siRNA delivery10.1002/ijc.31079 ↗
23. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells10.1038/cgt.2013.8 ↗
24. Polymeric Delivery of siRNA against Integrin-β1 (CD29) to Reduce Attachment and Migration of Breast Cancer Cells
25. Protein expression following non-viral delivery of plasmid DNA coding for basic FGF and BMP-2 in a rat ectopic model10.1016/j.biomaterials.2012.01.031 ↗
26. Additive Polyplexes to Undertake siRNA Therapy against CDC20 and Survivin in Breast Cancer Cells10.1021/acs.biomac.8b00918 ↗
27. Polyethylenimine-polyacrylic acid nanocomposites: type of bonding does influence the gene transfer efficacy and cytotoxicity10.1016/j.colsurfb.2015.12.007 ↗
28. Evidence supporting the safety of pegylated diethylaminoethyl-chitosan polymer as a nanovector for gene therapy applications10.2147/IJN.S252397 ↗
29. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution10.1021/mp800032f ↗
30. Toxicological consequences of extracellular hemoglobin: biochemical and physiological perspectives10.1089/ars.2009.2799 ↗
31. In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes10.1016/S0021-9258(18)89189-X ↗
32. Food and Drug Administration, Guidance for industry: immunogenicity assessment for therapeutic protein products, FDA-2013-d-0092 (2014).
33. The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia10.1182/blood.V100.4.1215.h81602001215_1215_1219 ↗
34. Expression and regulation of tumor necrosis factor α in normal and malignant ovarian epithelium10.1158/1535-7163.MCT-05-0303 ↗
35. Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer10.1038/sj.bjc.6601814 ↗
36. Effects of tumour necrosis factor on cardiovascular disease and cancer: a two-sample Mendelian randomization study10.1016/j.ebiom.2020.102956 ↗
37. Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management10.3748/wjg.v20.i46.17352 ↗
38. The concentration of tumor necrosis factor-α determines its protective or damaging effect on liver injury by regulating Yap activity10.1038/s41419-020-2264-z ↗
39. The inflammatory effects of TNF-α and complement component 3 on coagulation10.1038/s41598-018-20220-8 ↗
40. Respective roles of TNF-α and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice10.1038/sj.gt.3302885 ↗
41. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer10.1016/j.biopha.2018.09.177 ↗
42. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer10.1097/JTO.0000000000000193 ↗
43. Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain10.1186/1742-2094-6-9 ↗
44. Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers10.1523/JNEUROSCI.3376-06.2006 ↗
45. Increased Circulating Levels of Interleukin-6 Affect the Redox Balance in Skeletal Muscle
46. Fiber-Modified Adenovirus Vectors Decrease Liver Toxicity through Reduced IL-6 Production10.4049/jimmunol.178.3.1767 ↗
47. Shielding of lipid nanoparticles for siRNA delivery: impact on physicochemical properties, cytokine induction, and efficacy10.1038/mtna.2014.61 ↗
48. IFN-γ-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer10.1016/j.vaccine.2010.03.007 ↗
49. Interferon-gamma at the crossroads of tumor immune surveillance or evasion10.3389/fimmu.2018.00847 ↗
50. Interferon gamma in cancer immunotherapy10.1002/cam4.1700 ↗
51. Gamma interferon and lipopolysaccharide interact at the level of transcription to induce tumor necrosis factor alpha expression10.1128/IAI.69.5.2847-2852.2001 ↗
52. Sustained low-level expression of interferon-γ promotes tumor development: potential insights in tumor prevention and tumor immunotherapy10.1007/s00262-004-0654-1 ↗
53. The dark side of IFN-γ: its role in promoting cancer immunoevasion
54. IFN-γ causes aplastic anemia by altering hematopoietic stem/progenitor cell composition and disrupting lineage differentiation10.1182/blood-2014-01-549527 ↗
55. IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice10.1016/j.jaut.2014.02.003 ↗
56. Composite liposome-PEI/nucleic acid lipopolyplexes for safe and efficient gene delivery and gene knockdown10.1016/j.colsurfb.2017.06.022 ↗
57. Additive nanocomplexes of cationic lipopolymers for improved non-viral gene delivery to mesenchymal stem cells10.1039/C4TB02101K ↗
58. Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines
59. Food and Drug Administration, Additinal Standards For Human Blodd and Blood Products, 21CFR640 (2020).
60. Multiplex cytokine and antibody profile in cystic echinococcosis patients during a three-year follow-up in reference to the cyst stages10.1186/s13071-020-4003-9 ↗
61. The causes and consequences of variation in human cytokine production in health10.1016/j.coi.2018.05.012 ↗
62. A systematic comparison of lipopolymers for siRNA delivery to multiple breast cancer cell lines: in vitro studies10.1016/j.actbio.2019.11.036 ↗
63. BCR-Abl Silencing by siRNA: a Potent Approach to Sensitize Chronic Myeloid Leukemia Cells to Tyrosine Kinase Inhibitor Therapy10.1089/scd.2018.0196 ↗
64. Comparative toxicity of oleic acid and linoleic acid on Jurkat cells10.1016/j.clnu.2003.12.004 ↗
65. A Delicate Balance When Substituting a Small Hydrophobe onto Low Molecular Weight Polyethylenimine to Improve Its Nucleic Acid Delivery Efficiency10.1021/acsami.5b07929 ↗
66. Polymeric siRNA delivery targeting integrin-β1 could reduce interactions of leukemic cells with bone marrow microenvironment
67. Layer-by-layer assembly of liposomal nanoparticles with PEGylated polyelectrolytes enhances systemic delivery of multiple anticancer drugs10.1016/j.actbio.2014.08.021 ↗
68. Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines10.1016/j.jconrel.2013.05.025 ↗
69. DNA transfection and transfected cell viability using amphipathic asymmetric dendrimers10.1016/S0378-5173(00)00534-2 ↗
70. D.M. Domański, B. Klajnert, M. Bryszewska, Influence of PAMAM dendrimers on human red blood cells, in: Bioelectrochemistry, 2004: pp. 189–191. https://doi.org/10.1016/j.bioelechem.2003.09.023.10.1016/j.bioelechem.2003.09.023 ↗
71. Red cell hemolysis during processing and storage10.4103/0973-6247.33446 ↗
72. Co-delivery of paclitaxel and anti-VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy10.1080/10717544.2020.1827085 ↗
73. Biomimetic mucin modified PLGA nanoparticles for enhanced blood compatibility10.1016/j.jcis.2013.07.004 ↗
74. Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN141210.1056/NEJMoa063842 ↗
75. Negligible induction of IFN-γ, IL-12 and TNF-α by DNA-PEI 750 kDa/albumin complexes10.1016/j.cyto.2004.11.010 ↗
76. Propionic acid affects immune status and metabolism in adipose tissue from overweight subjects10.1111/j.1365-2362.2011.02590.x ↗
77. Impact of Short- and Medium-Chain Fatty Acids on Mitochondrial Function in Severe Inflammation10.1177/0148607113489833 ↗
78. Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes10.1002/hep.21752 ↗
79. Stearic acid induces proinflammatory cytokine production partly through activation of lactate-HIF1α pathway in chondrocytes10.1038/srep13092 ↗
80. The lauric acid-activated signaling prompts apoptosis in cancer cells10.1038/cddiscovery.2017.63 ↗
81. Lauric acid abolishes interferon-gamma (IFN-γ)-induction of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) expression in human macrophages10.1016/j.apjr.2015.06.005 ↗
82. A comparative evaluation of disulfide-linked and hydrophobically-modified PEI for plasmid delivery10.1163/092050610X496297 ↗
83. Particle size and activation threshold: a new dimension of danger signaling10.1182/blood-2009-11-247817 ↗
84. Pulmonary cytokine responses associated with PEI-DNA aerosol gene therapy10.1038/sj.gt.3301369 ↗
85. Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response10.1007/s11095-008-9693-1 ↗
86. Toxicity pathway focused gene expression profiling of PEI-based polymers for pulmonary applications10.1021/mp900278x ↗
87. Polyethylenimine-Mediated CpG Oligodeoxynucleotide Delivery Stimulates Bifurcated Cytokine Induction10.1021/acsbiomaterials.8b00049 ↗
88. A facile approach to enhance antigen response for personalized cancer vaccination10.1038/s41563-018-0028-2 ↗
89. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine10.1016/j.biomaterials.2009.11.003 ↗